search
Back to results

Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET) (RESET)

Primary Purpose

Differentiated Thyroid Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
rhTSH-stimulated I-124 dosimetry
Intra-therapeutic I-131 dosimetry
Sponsored by
Leiden University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Differentiated Thyroid Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years at the time of informed consent
  • Histologically or cytologically confirmed DTC (including papillary, follicular or Hürthle Cell carcinoma)
  • Progressive (biochemical or anatomic) disease for which lenvatinib is started as standard treatment at the discretion of the treating physician
  • Measurable disease at baseline imaging (F-18 FDG PET) according to the definition of the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) 1.0 with at least one lesion ≥1.0 cm in the longest diameter for a non-lymph node or ≥1.5 cm in the short axis for a lymph node.
  • RAI-R disease on structural imaging, defined as any one of the following:

    • Metastatic lesions that are not RAI-avid on a diagnostic or intra-therapeutic RAI scanperformed prior to enrolment in the current study
    • RAI-avid metastatic lesions which remained stable in size or progressed according to RECIST 1.1 criteria despite RAI treatment. Absence of response is observed during 6-9 months after high dose I-131 therapy.
  • No recent treatment for thyroid cancer:

    • No prior I-131 therapy is allowed <6 months prior to initiation of therapy on this protocol (a diagnostic study using <400 MBq of I-131 is not considered 131I therapy)
    • No external beam radiation therapy is allowed <4 weeks prior to initiation of therapy on this protocol. (Previous treatment with radiation for any indication is allowed if the investigator judges that the previous radiation does not significantly compromise patient safety on this protocol)
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (or Karnofsky ≥60%)
  • Life expectancy ≥3 months
  • Ability to swallow and retain orally-administered medication and no clinically significant gastrointestinal abnormalities that may alter absorption
  • Creatinine ≤1.5 mg/dL (≤133 µmol/L) or estimated glomerular filtration rate (eGFR) (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula) ≥50 mL/min/1.73m2 or 24-hour urine creatinine clearance ≥50 mL/min/1.73m2
  • Adequate blood coagulation function as evidenced by an international normalized ratio (INR) ≤1.5
  • Adequate bone marrow function with:

    • Absolute neutrophil count ≥1.5*10^9 /L
    • Hemoglobin ≥9 g/dL (5.6 mmol/L)
    • Platelets ≥100*10^9 /L
  • Adequate liver function with

    • Albumin ≥25 g/L
    • Total bilirubin <1.5x institutional upper limit of normal (ULN) with an exception for patients with Gilbert's syndrome
    • Aspartate aminotransferase and alanine aminotransferase ≤3x institutional ULN (≤5x ULN if subject has liver metastases)
  • Negative pregnancy test within 7 days prior to starting the study for premenopausal women. Women can be included without pregnancy test if they are either surgically sterile or have been postmenopausal for ≥1 year.
  • Sexually active women of childbearing potential must agree to use a highly effective method of contraception during the study and for at least 6 months after the last study treatment administration.Sexually active males patients must agree to use condom during the study and for at least 6 months after the last study treatment administration. Also, it is recommended their women of childbearing potential partner use a highly effective method of contraception. Effective methods of contraception are defined as those, which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intrauterine devices). At the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)
  • Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol

Exclusion Criteria:

  • Concomitant or previous malignancies within the last 3 years. Patients are eligible for this study if they have been disease-free of the previous malignancy for at least 3 years, have a history of completely resected non-melanoma skin cancer and/or have indolent secondary malignancies.
  • Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression
  • Evidence of cardiovascular risk including any of the following:

    • Clinically relevant arrhythmias
    • Acute coronary syndromes, severe/unstable angina
    • Symptomatic congestive heart failure
  • Use of other investigational drugs within 28 days preceding the first dose of treatment in this study or during the study
  • Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to lenvatinib and/or to Thyrotropin alfa (human recombinant thyrotropin) or other known contents of the two drugs.
  • Inability to follow a low iodine diet or requiring medication with high content in iodide (e.g. amiodarone)
  • Patients who received iodinated intravenous contrast as part of a radiographic procedure within 6-8 weeks of study registration. Patients are eligible for this study if urinary iodine analysis reveals that the excess iodine has been adequately cleared after the last intravenous contrast administration
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant, lactating or breast feeding women
  • Any medical or other condition that in the opinion of the investigator(s) would preclude the participation in a clinical study
  • Unwillingness or inability to comply with study and follow-up procedures

Sites / Locations

  • Leiden University Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Cohort 1

Cohort 2

Arm Description

Study procedures Lenvatinib during week 1-12 rhTSH-stimulated I-124 dosimetry at week 0, 6 and 12 rhTSH-stimulated I-131 therapy at week 13 (if eligible) Intra-therapeutic I-131 dosimetry at week 13 (if eligible) Biopsy at week 0 and 6 F-18 FDG PET/CT at week 0, 6, 12, 24 and 36 Tg levels at week 0, 6, 12, 24 and 36 QoL assessment at week 0, 6, 12, 24 and 36

Study procedures (in case of 12-wk lenvatinib): Lenvatinib during week 1-12 rhTSH-stimulated I-124 dosimetry at week 0 and 12 rhTSH-stimulated I-131 therapy at week 13 (if eligible) Intra-therapeutic I-131 dosimetry at week 13 (if eligible) Biopsy at week 0 and 6 F-18 FDG PET/CT at week 0, 12, 24 and 36 Tg levels at week 0, 6, 12, 24 and 36 QoL assessment at week 0, 6, 12, 24 and 36 Study procedures (in case of 6-wk lenvatinib) Lenvatinib during week 1-6 rhTSH-stimulated I-124 dosimetry at week 0 and 6 rhTSH-stimulated I-131 therapy at week 13 (if eligible) Intra-therapeutic I-131 dosimetry at week 13 (if eligible) Biopsy at week 0 and 6 F-18 FDG PET/CT at week 0, 6, 12, 24, 30 and 36 Tg levels at week 0, 6, 12, 24, 30 and 36 QoL assessment at week 0, 6, 12, 24, 30 and 36

Outcomes

Primary Outcome Measures

Fraction of RAI-R thyroid cancer patients who are eligible for I-131 therapy after 6- or 12-week lenvatinib treatment
Patients are deemed eligible for I-131 therapy if the therapeutic activity (max. 7.4 GBq) will lead to (1) an expected absorbed dose >20 Gy in at least one lesion, (2) a blood dose <2 Gy and (3) whole body retention <3.0 or 4.4 GBq at 48h post-ingestion in presence or absence of diffuse pulmonary metastases, respectively.

Secondary Outcome Measures

Extent of RAI uptake at baseline and after 6- or 12-week lenvatinib
Assessing expected absorbed dose [Gy] per lesion or critical organ using I-124 PET/CT, whole body counting and blood sampling
Optimal duration of lenvatinib treatment for maximum redifferentiation to occur
Either 6 of 12 weeks after comparing (1) fraction of patients eligible for I-131 therapy, (2) expected absorbed dose [Gy] per lesion or critical organ and (3) toxicity incidence and severity
Extent of RAI uptake after I-131 therapy
Assessing expected absorbed dose [Gy] per lesion or critical organ using intra-therapeutic I-131 SPECT/CT, whole body counting and blood sampling
Metabolic treatment response using F-18 FDG PET
Metabolic response will be assessed using PERCIST v1.0. Tumor response is defined as complete response, partial response, stable response or progressive disease.
Unstimulated (TSH suppressed) thyroglobulin levels
Assessment of biochemical treatment response
Overall survival at 36 weeks after initation of lenvatinib
Best objective response at 36 weeks after initation of lenvatinib
Progression free survival at 36 weeks after initation of lenvatinib
Incidence and severity of toxicities according to CTCAE 5.0
Quality of life using standardized questionnaire ThycaQoL
Quality of life using standardized questionnaire RAND36
Quality of life using standardized questionnaire EQ5D5L
Quality of life using standardized questionnaire Distress thermometer

Full Information

First Posted
April 9, 2021
Last Updated
October 5, 2023
Sponsor
Leiden University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04858867
Brief Title
Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)
Acronym
RESET
Official Title
Reinducing Radioiodine-sensitivity in Radioiodine-refractory Differentiated Thyroid Cancer Using Lenvatinib (RESET)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 10, 2022 (Actual)
Primary Completion Date
January 1, 2025 (Anticipated)
Study Completion Date
June 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Leiden University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a single-centre open label phase II study evaluating the effect of lenvatinib treatment for restoring radioiodine uptake and retention in radioiodine-refractory (RAI-R) thyroid cancer to warrant I-131 therapy.
Detailed Description
RAI-R DTC patients starting standard-of-care lenvatinib treatment will be included in this study. Prior to lenvatinib treatment, patients will undergo I-124 PET/CT to quantify RAI uptake and retention at baseline. The first half of the intended sample size (cohort 1) will be treated with lenvatinib for a total of 12 weeks. After 6- and 12-week treatment, patients will undergo I-124 PET/CT dosimetry to evaluate the redifferentiation effect, assess expected absorbed lesion doses and maximum tolerable activity. Results between 6- and 12-week lenvatinib treatment will be compared to select the lenvatinib treatment duration that leads to highest extent of redifferentiation. The next patients (cohort 2) will then receive lenvatinib for either 6 or 12 weeks. Patients will undergo subsequent I-131 therapy if a clinically meaningful lesion dose is expected and toxicity is deemed acceptable. For all patients eligible for I-131 therapy, lenvatinib is discontinued prior to administration of I-131 and intra-therapeutic I-131 SPECT dosimetry will be performed for dose verification. Patients who are not eligible for I-131 therapy, will continue lenvatinib treatment at the discretion of the treating physician. Biopsies are performed at baseline and after 6-week lenvatinib treatment to evaluate alterations at the transcriptional and translational level in biopted tumor lesions. Patients will be followed up according to current guidelines for a total of 9 months after initiating lenvatinib treatment. Metabolic and biochemical response will be assessed using F-18 FDG PET/CT and Tg levels, respectively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Differentiated Thyroid Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1
Arm Type
Other
Arm Description
Study procedures Lenvatinib during week 1-12 rhTSH-stimulated I-124 dosimetry at week 0, 6 and 12 rhTSH-stimulated I-131 therapy at week 13 (if eligible) Intra-therapeutic I-131 dosimetry at week 13 (if eligible) Biopsy at week 0 and 6 F-18 FDG PET/CT at week 0, 6, 12, 24 and 36 Tg levels at week 0, 6, 12, 24 and 36 QoL assessment at week 0, 6, 12, 24 and 36
Arm Title
Cohort 2
Arm Type
Other
Arm Description
Study procedures (in case of 12-wk lenvatinib): Lenvatinib during week 1-12 rhTSH-stimulated I-124 dosimetry at week 0 and 12 rhTSH-stimulated I-131 therapy at week 13 (if eligible) Intra-therapeutic I-131 dosimetry at week 13 (if eligible) Biopsy at week 0 and 6 F-18 FDG PET/CT at week 0, 12, 24 and 36 Tg levels at week 0, 6, 12, 24 and 36 QoL assessment at week 0, 6, 12, 24 and 36 Study procedures (in case of 6-wk lenvatinib) Lenvatinib during week 1-6 rhTSH-stimulated I-124 dosimetry at week 0 and 6 rhTSH-stimulated I-131 therapy at week 13 (if eligible) Intra-therapeutic I-131 dosimetry at week 13 (if eligible) Biopsy at week 0 and 6 F-18 FDG PET/CT at week 0, 6, 12, 24, 30 and 36 Tg levels at week 0, 6, 12, 24, 30 and 36 QoL assessment at week 0, 6, 12, 24, 30 and 36
Intervention Type
Radiation
Intervention Name(s)
rhTSH-stimulated I-124 dosimetry
Intervention Description
Preparation: Low iodine diet 7 days prior to I-124 ingestion until 24 hours post-ingestion Thyrogen injections 24 and 48h prior to I-124 ingestion Procedures following Jentzen et al: Ingestion of capsule with 37±10% MBq I-124 I-124 PET/CT at 24 and 96h post-ingestion Blood draws at 2, 24 and 96h post-ingestion Whole body counting at 2, 24 and 96h post-ingestion
Intervention Type
Radiation
Intervention Name(s)
Intra-therapeutic I-131 dosimetry
Intervention Description
Procedures following EANM guidelines: I-131 SPECT/CT at 2, 6, 24, 96 and 144h post-ingestion Blood draws at 2, 6, 24, 96 and 144h post-ingestion Whole body counting at 2, 6, 24, 96 and 144h post-ingestion
Primary Outcome Measure Information:
Title
Fraction of RAI-R thyroid cancer patients who are eligible for I-131 therapy after 6- or 12-week lenvatinib treatment
Description
Patients are deemed eligible for I-131 therapy if the therapeutic activity (max. 7.4 GBq) will lead to (1) an expected absorbed dose >20 Gy in at least one lesion, (2) a blood dose <2 Gy and (3) whole body retention <3.0 or 4.4 GBq at 48h post-ingestion in presence or absence of diffuse pulmonary metastases, respectively.
Time Frame
2-3 months after completed inclusion of all study participants
Secondary Outcome Measure Information:
Title
Extent of RAI uptake at baseline and after 6- or 12-week lenvatinib
Description
Assessing expected absorbed dose [Gy] per lesion or critical organ using I-124 PET/CT, whole body counting and blood sampling
Time Frame
0, 6, 12 weeks after inclusion
Title
Optimal duration of lenvatinib treatment for maximum redifferentiation to occur
Description
Either 6 of 12 weeks after comparing (1) fraction of patients eligible for I-131 therapy, (2) expected absorbed dose [Gy] per lesion or critical organ and (3) toxicity incidence and severity
Time Frame
3 months after completed inclusion of cohort 1
Title
Extent of RAI uptake after I-131 therapy
Description
Assessing expected absorbed dose [Gy] per lesion or critical organ using intra-therapeutic I-131 SPECT/CT, whole body counting and blood sampling
Time Frame
7 or 12 weeks after inclusion
Title
Metabolic treatment response using F-18 FDG PET
Description
Metabolic response will be assessed using PERCIST v1.0. Tumor response is defined as complete response, partial response, stable response or progressive disease.
Time Frame
0, 6, 12, 24, 30, 36 weeks after inclusion
Title
Unstimulated (TSH suppressed) thyroglobulin levels
Description
Assessment of biochemical treatment response
Time Frame
0, 6, 12, 24, 30, 36 weeks after inclusion
Title
Overall survival at 36 weeks after initation of lenvatinib
Time Frame
9 months after inclusion
Title
Best objective response at 36 weeks after initation of lenvatinib
Time Frame
9 months after inclusion
Title
Progression free survival at 36 weeks after initation of lenvatinib
Time Frame
9 months after inclusion
Title
Incidence and severity of toxicities according to CTCAE 5.0
Time Frame
during 0-9 months after inclusion
Title
Quality of life using standardized questionnaire ThycaQoL
Time Frame
0, 6, 12, 24, 30, 36 weeks after inclusion
Title
Quality of life using standardized questionnaire RAND36
Time Frame
0, 6, 12, 24, 30, 36 weeks after inclusion
Title
Quality of life using standardized questionnaire EQ5D5L
Time Frame
0, 6, 12, 24, 30, 36 weeks after inclusion
Title
Quality of life using standardized questionnaire Distress thermometer
Time Frame
0, 6, 12, 24, 30, 36 weeks after inclusion
Other Pre-specified Outcome Measures:
Title
NIS expression in biopted tumor lesion(s) at baseline and 6 weeks after lenvatinib
Description
An explorative endpoint of this study is to evaluate alterations at the transcriptional and translational level in biopted tumour lesions before and after lenvatinib treatment and to determine whether treatment response is related to genetical profiles
Time Frame
0 and 6 weeks after inclusion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years at the time of informed consent Histologically or cytologically confirmed DTC (including papillary, follicular or Hürthle Cell carcinoma) Progressive (biochemical or anatomic) disease for which lenvatinib is started as standard treatment at the discretion of the treating physician Measurable disease at baseline imaging (F-18 FDG PET) according to the definition of the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) 1.0 with at least one lesion ≥1.0 cm in the longest diameter for a non-lymph node or ≥1.5 cm in the short axis for a lymph node. RAI-R disease on structural imaging, defined as any one of the following: Metastatic lesions that are not RAI-avid on a diagnostic or intra-therapeutic RAI scanperformed prior to enrolment in the current study RAI-avid metastatic lesions which remained stable in size or progressed according to RECIST 1.1 criteria despite RAI treatment. Absence of response is observed during 6-9 months after high dose I-131 therapy. No recent treatment for thyroid cancer: No prior I-131 therapy is allowed <6 months prior to initiation of therapy on this protocol (a diagnostic study using <400 MBq of I-131 is not considered 131I therapy) No external beam radiation therapy is allowed <4 weeks prior to initiation of therapy on this protocol. (Previous treatment with radiation for any indication is allowed if the investigator judges that the previous radiation does not significantly compromise patient safety on this protocol) Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (or Karnofsky ≥60%) Life expectancy ≥3 months Ability to swallow and retain orally-administered medication and no clinically significant gastrointestinal abnormalities that may alter absorption Creatinine ≤1.5 mg/dL (≤133 µmol/L) or estimated glomerular filtration rate (eGFR) (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula) ≥50 mL/min/1.73m2 or 24-hour urine creatinine clearance ≥50 mL/min/1.73m2 Adequate blood coagulation function as evidenced by an international normalized ratio (INR) ≤1.5 Adequate bone marrow function with: Absolute neutrophil count ≥1.5*10^9 /L Hemoglobin ≥9 g/dL (5.6 mmol/L) Platelets ≥100*10^9 /L Adequate liver function with Albumin ≥25 g/L Total bilirubin <1.5x institutional upper limit of normal (ULN) with an exception for patients with Gilbert's syndrome Aspartate aminotransferase and alanine aminotransferase ≤3x institutional ULN (≤5x ULN if subject has liver metastases) Negative pregnancy test within 7 days prior to starting the study for premenopausal women. Women can be included without pregnancy test if they are either surgically sterile or have been postmenopausal for ≥1 year. Sexually active women of childbearing potential must agree to use a highly effective method of contraception during the study and for at least 6 months after the last study treatment administration.Sexually active males patients must agree to use condom during the study and for at least 6 months after the last study treatment administration. Also, it is recommended their women of childbearing potential partner use a highly effective method of contraception. Effective methods of contraception are defined as those, which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intrauterine devices). At the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.) Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol Exclusion Criteria: Concomitant or previous malignancies within the last 3 years. Patients are eligible for this study if they have been disease-free of the previous malignancy for at least 3 years, have a history of completely resected non-melanoma skin cancer and/or have indolent secondary malignancies. Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression Evidence of cardiovascular risk including any of the following: Clinically relevant arrhythmias Acute coronary syndromes, severe/unstable angina Symptomatic congestive heart failure Use of other investigational drugs within 28 days preceding the first dose of treatment in this study or during the study Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to lenvatinib and/or to Thyrotropin alfa (human recombinant thyrotropin) or other known contents of the two drugs. Inability to follow a low iodine diet or requiring medication with high content in iodide (e.g. amiodarone) Patients who received iodinated intravenous contrast as part of a radiographic procedure within 6-8 weeks of study registration. Patients are eligible for this study if urinary iodine analysis reveals that the excess iodine has been adequately cleared after the last intravenous contrast administration Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements. Pregnant, lactating or breast feeding women Any medical or other condition that in the opinion of the investigator(s) would preclude the participation in a clinical study Unwillingness or inability to comply with study and follow-up procedures
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maaike Dotinga, MSc
Phone
+31715263695
Email
M.Dotinga@lumc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Dennis Vriens, MD, PhD
Phone
+31715299703
Email
D.Vriens@lumc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ellen Kapiteijn, MD, PhD
Organizational Affiliation
LUMC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dennis Vriens, MD, PhD
Organizational Affiliation
LUMC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Leiden University Medical Center
City
Leiden
State/Province
Zuid-Holland
ZIP/Postal Code
2333ZA
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ellen Kapiteijn, MD, PhD
Phone
+31715263206
Email
H.W.Kapiteijn@lumc.nl
First Name & Middle Initial & Last Name & Degree
Maaike Dotinga, MSc
Phone
+31715263695
Email
M.Dotinga@lumc.nl

12. IPD Sharing Statement

Citations:
PubMed Identifier
32744039
Citation
Dotinga M, Vriens D, van Velden F, Heijmen L, Nagarajah J, Hicks R, Kapiteijn E, de Geus-Oei LF. Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. Q J Nucl Med Mol Imaging. 2020 Sep;64(3):250-264. doi: 10.23736/S1824-4785.20.03264-1.
Results Reference
background
PubMed Identifier
36553163
Citation
Dotinga M, Vriens D, van Velden FHP, Stam MK, Heemskerk JWT, Dibbets-Schneider P, Pool M, Rietbergen DDD, de Geus-Oei LF, Kapiteijn E. Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial. Diagnostics (Basel). 2022 Dec 14;12(12):3154. doi: 10.3390/diagnostics12123154.
Results Reference
background

Learn more about this trial

Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)

We'll reach out to this number within 24 hrs